Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | TERT | O14746 | 3/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12578156 | 0.78 | ALDH1A1 (0.44) | CA12CA1CA9 | |
| SCHEMBL25391492 | 0.77 | TERT (0.41) | TERT | |
| SCHEMBL30570368 | 0.77 | TERT (0.41) | TERT | |
| SCHEMBL12577789 | 0.77 | CA12 (0.34) | CA12CA1CA9PREP | |
| SCHEMBL3340077 | 0.75 | HTR7 (0.41) | TERT | |
| SCHEMBL2027100 | 0.75 | BRD4 (0.49) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL12640965 | 0.75 | TERT (0.40) | TERTHSP90AA1 | |
| SCHEMBL13117421 | 0.74 | PREP (0.35) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL5799300 | 0.73 | CA12 (0.37) | CA12CA1CA9PREPTERT | |
| SCHEMBL1251338 | 0.73 | CA12 (0.40) | CA12CA1CA9PREPHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-2011788-A1 | OXADIAZOLIDINEDIONE COMPOUND | Astellas Pharma Inc. (JP) | 2009-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186909-A1 | Oxadiazolidinedione Compound | GPR119, GPR39, GPR65 | CA12 4396/4885CA1 4091/4885CA9 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.